Clinical trials: Spondyloarthropathy
Spondyloarthropathies
Certolizumab Pegol in Subjects With Active Axial Spondyloarthritis
The study is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of two dose regimens of Certolizumab Pegol (CZP) in subjects with active axial Spondyloarthritis (axial…
- Trial name
- NCT01087762
- Testing
- CZP 200 mg Q2W, CZP 400 mg Q4W
- Where
- 104 sites in United States, Argentina and 13 more
- Volunteers
- 325 people
- Sponsor
- UCB BIOSCIENCES GmbH